Sirio Pharma Balance Sheet Health

Financial Health criteria checks 5/6

Sirio Pharma has a total shareholder equity of CN¥2.6B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 46.1%. Its total assets and total liabilities are CN¥5.3B and CN¥2.7B respectively. Sirio Pharma's EBIT is CN¥438.1M making its interest coverage ratio 4.4. It has cash and short-term investments of CN¥637.4M.

Key information

46.1%

Debt to equity ratio

CN¥1.19b

Debt

Interest coverage ratio	4.4x
Cash	CN¥637.40m
Equity	CN¥2.57b
Total liabilities	CN¥2.71b
Total assets	CN¥5.28b

Recent financial health updates

Recent updates

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

Oct 14

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sep 23

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Aug 01

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Jun 30

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

Financial Position Analysis

Short Term Liabilities: 300791's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥751.7M).

Long Term Liabilities: 300791's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥2.0B).

Debt to Equity History and Analysis

Debt Level: 300791's net debt to equity ratio (21.4%) is considered satisfactory.

Reducing Debt: 300791's debt to equity ratio has increased from 18% to 46.1% over the past 5 years.

Debt Coverage: 300791's debt is well covered by operating cash flow (31.7%).

Interest Coverage: 300791's interest payments on its debt are well covered by EBIT (4.4x coverage).

Sirio Pharma Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 29%

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Price target decreased by 7.2% to CN¥29.75

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Now 21% overvalued

Now 21% overvalued

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investor sentiment deteriorates as stock falls 27%

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Price target increased by 7.8% to CN¥41.67

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 22% undervalued

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

Investor sentiment deteriorated over the past week

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥89.00

Sirio Pharma Co., Ltd. announced a financing transaction

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies